Head-to-head · Cost-Efficiency Index
Fitish vs Claya
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Fitish
Shoppers who want a genuinely all-in price with no separate consult fee, or a fixed low-dose 'microdose' option.
Visit FitishClaya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaThe verdict
Fitish and Claya tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Fitish (ranked #92, a hair above #97) — Shoppers who want a genuinely all-in price with no separate consult fee, or a fixed low-dose 'microdose' option. But Claya is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Fitish.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Fitish | Claya |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $219/mo (microdose tier, plus a separate fee, compounded) | $149/mo (all doses, compounded) |
| Tirzepatide / mo | $339/mo (microdose tier, compounded) | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $2,628 | $1,788 |
| Tirzepatide / yr (modeled) | $4,068 | $2,388 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #92 | #97 |
Fitish
69/100Where the value is
- Price genuinely includes consult, medication, and shipping — confirmed in the product page's own text, not just marketing copy
- A real microdose tier exists at a meaningfully lower fixed price for both drugs
- Injectable and oral tablet formats both offered
The tradeoffs
- No stated minimum commitment or cancellation terms found on the product pages
- No named prescriber, medical director, or specific compounding pharmacy
Regulatory note: the FDA issued a warning letter to FITISH in June 2026. We still list and link to Fitish; you should know the letter is on the public record before you decide.
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.